Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

  • Webinar scheduled for Thursday 17.11.2022at 11:00 AM EST

  • It features a key discussion by thought leaders on the current treatment landscape

NEW YORK, November 9, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on developing oral drug delivery platforms, today announced that it will host a data presentation on newly published safety and efficacy data from the 2 trials of its oral insulin candidate (ORMD-0801) to reduce liver fat in patients with type 2 diabetes (“T2D”) with nonalcoholic steatohepatitis (“NASH”) at Thursday 17.11.2022at 11:00 AM ET.

Oramed Logo

Oramed Logo

Professor Yaron IlanMDdirector of the Department of Medicine at Hebrew University-Hadassah Medical Center, i Joel NeutelMDdirector of research, at the Orange County Research Center and Memorial Research Medical Clinic, will comment on these data and the need for a NASH treatment that is safe and well tolerated.

The official presentation will be followed by a live question and answer session with Dr. Ilan and Dr. Neutel, who were the principal investigators of this study.

To register for the event, click on the following link: https://touchconference.zoom.us/vebinar/register/VN_di3jzksKKA6kBKZdT5a0_g

The live and archived webinar of this event can be accessed on Oramed’s website under Events and Presentations.

Professor Yaron IlanMD
Ph.D. Yaron Ilan is the director of the Department of Medicine at Hebrew University– Hadassah Medical Center. Dr. Ilan was the vice dean Hebrew University– Hadassah Medical School. Dr. Ilan was a visiting professor at Harvard University, working on new immunotherapies. His main area of ​​research is the development of immunomodulatory drugs for fatty liver disease, diabetes, inflammatory bowel disease and liver cancer. Dr. Ilan holds over 50 patents for discoveries based on his innovative research and is the author of more than 300 articles. He is the inventor of several drugs and medical devices developed by pharmaceutical companies, several of which have reached the clinical market. Dr. Ilan is the founder of several companies and is the medical director and advisor for biotech companies.

Also Read :  Two accomplished architecture firms selected for Brown’s planned integrated life sciences building

Joel NeutelMD
Dr. Neutel is director of research at the Orange County Research Center in Orange County, California and at the Memorial Research Medical Clinic in Long Beach, California, where he served as principal investigator on several hundred multinational cardiovascular and metabolic trials. Dr. Neutel has extensive experience serving the biopharmaceutical industry in the areas of clinical and academic research, as well as marketing strategic planning. After graduating in medicine from the University of the Witwatersrand in Johannesburg, South AfricaDr. Neutel completed his internship and specialization in internal medicine at the Medical Center of the Administration for Veteran Affairs in Long beach and The University of California, Irvine. Dr. Neutel is the author of numerous abstracts, journal articles, and book chapters. He has conducted extensive research in disciplines such as cardiovascular medicine, endocrinology, and central nervous system disorders, with particular attention to the pharmacotherapy of diseases in these areas.

About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdak/TASE: ORMP) is a platform technology pioneer in oral solutions for drugs currently delivered by injection. Founded in 2006, with offices in United States and Israel, Oramed has developed a new technology for oral protein delivery (POD™). Oramed seeks to transform the treatment of diabetes through its own lead candidate, ORMD-0801, which is being evaluated in two pivotal phase 3 trials and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (glucagon-like peptide-1) analog capsule (ORMD-0901).

Also Read :  Reaching new heights in largest ever genome study

For more information visit www.oramed.com

Forward-looking statements
This press release contains forward-looking statements. For example, we use forward-looking statements when we talk about ORMD-0801’s potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historical results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based only on the current expectations of Oramed’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties related to progress, timing, costs and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional financing necessary to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market demands; delays or obstacles in initiating our clinical trials; changes in legislation; impossibility of timely development and introduction of new technologies, products and applications; lack of validation of our technology as we move forward and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is necessary for the development of our products; unforeseen scientific difficulties that may develop in our process; higher cost of the final product than expected; loss of market share and pressure on prices as a result of competition; laboratory results that do not translate to equally good results in real-world conditions; our patents may not be sufficient; and finally that the products may harm recipients, all of which could cause Oramed’s actual results or performance to differ materially from those anticipated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly announce any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, we refer to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Also Read :  Now is not the time for a reckless gamble with Britain’s future, says ANGELA RAYNER | Express Comment | Comment

Company contact
Zach Herschfuss
[email protected]



See original content: https://www.prnevsvire.com/nevs-releases/oramed-to-host-vebinar-highlighting-detailed-safeti-and-efficaci-data-from-its-positive-phase-2-clinical- trial-of-ormd-0801-for-nash-301673007.html

SOURCE Oramed Pharmaceuticals Inc.


Leave a Reply

Your email address will not be published.